Weekly Digest Nr 18 | Week 21 | 20-24/05/2024

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH IN THE EU

HEALTH POLICY NEWS

- ≡ ECDC/EC/EFSA Country visit to Kosovo to advance One Health responses against antimicrobial resistance
- **Pesticide Action Network Europe** EU Pesticide Committee neglects health and environment

SCIENTIFIC PUBLICATIONS

- **Nature** A unifying modelling of multiple land degradation pathways in Europe
- **The Lancet -** <u>The Lancet Series on Antimicrobial Resistance: The need for sustainable access to effective</u> antibiotics

PUBLIC HEALTH REPORTS

- **Quadripartite** New guidance for One Health field epidemiology workforce development
- **EMA** Medical devices: new guidance for industry and notified bodies
- **JRC -** Suppressing indoor pathogen transmission: A Technology Foresight study
- **ECDC** Challenges and approaches for effective communication around the benefit and risk balance of vaccination
- **WOAH -** Animal Health Situation Worldwide Report 2024
- **WHO -** Annual World Health Statistics Report 2024

HEALTH POLICY BRIEFS

- Global Strategy Lab AMR Policy Accelerator: <u>Unifying Global Targets to Mobilize Global Action on Antimicrobial Resistance</u>
- **NHS England** Antimicrobial products subscription model: guidance on commercial arrangements
- **ICARS** A Year in Review 2023
- **EC** <u>Health consequences of prolonged exposure to multiple industrial air pollutants</u>
- **Welcome Trust -** Driving action on antimicrobial resistance (AMR) in 2024
- **The Lancet** − <u>Infographic on Antimicrobial resistance</u>: an enormous, growing, and unevenly distributed threat to global health
- **The Investor Action on AMR (IAAMR) initiative -** <u>Calling on global leaders and policymakers to combat</u>
 AMR
- = Access to Medicines Foundation:
 - Five themes delegates can engage the pharmaceutical industry on
 - How can pharma get the few promising drugs in development to patients battling superbugs?

CONFERENCES AND WEBINARS

- **Global AMR R&D Hub** <u>Launch of The Lancet Series on Antimicrobial Resistance</u>, 28 May
- **US National Academies** Advancing Data Sharing to Strengthen One Health Effectiveness: From Ideas to Action, 11 June
- ECHA/EFSA/EEA Research needs for protecting human health and the environment an EU agencies' perspective on a regulatory framework, current challenges and how scientific research projects could contribute to bridging knowledge gaps, 18 June
- **European Patient Forum** New Webinar Series: <u>Amplifying Patient Advocacy On Antimicrobial</u> <u>Resistance (AMR)</u>, 20 June

Weekly Digest Nr 18 | Week 21 | 20-24/05/2024

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH IN THE EU

■ WHO - Strategic Round Table on AMR webcast, 31 May 13:00 - 14:15 CEST (Geneva time)

REGULATORY NEWS

- \equiv EC:
 - Commission welcomes designation of European medicines network as WHO listed authority
 - Extension approved of the <u>delegated regulation of the Review Programme</u> for the systematic examination of all existing biocidal active substances from 31 December 2024 to 31 December 2030
 - Communication on the European Health Union: acting together for people's health
- Adoption of <u>new rules for joint clinical assessments of human medicines</u> under the Regulation on Health Technology Assessment (HTA)

TENDER PUBLICATIONS

- **ECDC/EFSA** <u>Provision of support to EFSA and to ECDC in the production of the EU One Health Zoonoses report</u>
- **HADEA -** Speed up the development of and access to innovative medical countermeasures Point of care metagenomic sequencing for universal pathogen detection

OPEN CONSULTATIONS

- **ECHA** <u>consultations</u> on alternatives to biocidal active substances and their impact on society and other relevant factors for derogation conditions
- **European partnership OHAMR -** Online Consultation on the final draft of the Strategic Research and Innovation Agenda of the future OHAMR Partnership, deadline 30 May

TRAININGS

 \equiv

APPLICATIONS

FAO - <u>Call for members: Expert Advisory Group on Strategic Framework for Early Warning of Animal</u> Health Threats

LEGAL NOTICE

- = RESINFIT is financed entirely by Inserm and receives no external funding or sponsorship from private organizations.
- = RESINFIT cannot provide any guarantees and cannot be held liable for any errors, inaccuracies or incompleteness of any information given on this digest or by any other third party.
- = The views and opinions expressed by individual authors of articles, presentations or discussion/opinion papers etc. do not necessarily reflect those of RESINFIT.
- RESINFIT provides links to many websites created and maintained by third party public and/or private organizations. The presence of a link is not a RESINFIT endorsement of the site. Upon following a link to a third-party website, users are leaving RESINFIT and are subject to the privacy and security policies of the owners/sponsors of the third-party website(s). RESINFIT is not responsible for the information collection practices of non-X sites.